EyePoint Pharmaceuticals, Inc. (EYPT) Income Statement
EYPT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsEYPT revenue and net income
Where EYPT's revenue goes
2025Each bar shows an amount and its share of revenue. EYPT kept −739.4% of revenue as net income.
EYPT profit margins
EYPT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −27.5% | −8.8% | −1.8% | +1.7% |
| Gross profit | −25.9% | −4.0% | +0.5% | +1.0% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
EYPT quarterly EPS vs estimates
EyePoint Pharmaceuticals beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.81).
EYPT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $5.9M | $7.5M | $1.6M |
| Cost of revenue | $2.1M | $3.7M | $4.6M | $8.3M | $8.2M | $5.8M | $2.7M | $18.5M | $16.2M | $14.9M |
| Gross profit | $29.3M | $39.6M | $41.4M | $33.1M | $28.8M | $28.6M | $17.7M | −$13.9M | $7.5M | $1.6M |
| Research & development | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M | $17.4M | $15.4M | $20.8M | $14.9M | $14.4M |
| Sales, general & admin | $51.7M | $52.5M | $51.8M | $60.3M | $53.1M | $46.0M | $47.7M | $25.1M | $11.2M | $9.0M |
| Total operating expenses | $272.7M | $185.4M | $116.5M | $132.7M | $84.0M | $65.9M | $65.5M | $52.3M | $26.1M | $23.4M |
| Operating income | −$243.4M | −$145.9M | −$75.1M | −$99.6M | −$55.3M | −$37.3M | −$47.9M | −$49.1M | −$18.6M | −$21.8M |
| Interest income | $11.8M | $15.1M | $6.9M | $2.1M | $292,000 | $58,000 | $1.1M | $20.2M | $101,000 | $91,000 |
| Interest expense | $33,000 | $14,000 | $1.2M | $3.2M | $5.5M | $7.3M | $6.2M | $720,000 | $720,000 | $0 |
| Income before taxes | −$231.7M | −$130.8M | −$70.7M | −$102.3M | −$58.4M | −$45.4M | −$56.8M | −$89.4M | −$18.5M | −$21.7M |
| Income taxes | $279,000 | $90,000 | $83,000 | $22.3M | $5.5M | $7.3M | $6.2M | −$25.6M | −$815,000 | −$155,000 |
| Net income | −$232.0M | −$130.9M | −$70.8M | −$102.3M | −$58.4M | −$45.4M | −$56.8M | −$53.2M | −$18.5M | −$21.5M |
| EBITDA | −$229.3M | −$129.2M | −$69.0M | −$96.6M | −$50.1M | −$35.5M | −$48.0M | −$46.5M | −$17.8M | −$20.9M |
| EPS (diluted) | −$3.16 | −$2.31 | −$1.83 | −$2.69 | −$2.09 | −$3.40 | −$5.20 | −$6.01 | −$5.90 | −$5.50 |
| Gross margin | 93.4% | 91.4% | 89.9% | 79.9% | 77.9% | 83.1% | 86.8% | −237.9% | 100.0% | 100.0% |
| Operating margin | −776.0% | −337.1% | −163.1% | −240.6% | −149.6% | −108.3% | −235.0% | −838.8% | −246.4% | −1,344.1% |
| Net margin | −739.4% | −302.4% | −153.8% | −247.0% | −158.1% | −131.8% | −278.9% | −908.0% | −245.2% | −1,330.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $507,000 | $696,000 | $620,000 | $966,000 | $5.3M | $24.5M | $11.6M | $10.5M | $9.5M | $11.7M | $14.0M | $15.2M |
| Cost of revenue | $0 | $528,000 | $375,000 | $721,000 | $165,000 | $805,000 | $816,000 | $736,000 | $1.4M | $759,000 | $998,000 | $1.2M |
| Gross profit | $507,000 | $168,000 | $245,000 | $245,000 | $5.2M | $23.6M | $10.8M | $9.8M | $8.1M | $10.9M | $13.0M | $14.0M |
| Research & development | $83.6M | $72.1M | $59.2M | $47.8M | $55.5M | $58.6M | $43.4M | $29.5M | $29.8M | $30.1M | $18.0M | $17.4M |
| Sales, general & admin | $14.3M | $15.2M | $11.4M | $14.5M | $11.9M | $13.9M | $12.6M | $13.0M | $12.8M | $14.1M | $11.4M | $11.0M |
| Total operating expenses | $97.9M | $87.4M | $70.6M | $62.3M | $67.4M | $72.5M | $56.0M | $42.5M | $42.6M | $44.2M | $29.4M | $28.4M |
| Operating income | −$97.4M | −$87.2M | −$70.3M | −$62.0M | −$62.2M | −$48.8M | −$45.2M | −$32.7M | −$34.5M | −$33.3M | −$16.4M | −$14.4M |
| Interest income | $2.9M | $2.3M | $3.0M | $2.3M | $2.9M | $3.6M | $3.9M | $3.4M | $3.7M | $4.0M | $2.3M | $1.8M |
| Interest expense | — | — | — | — | — | — | $14,000 | $0 | $0 | $0 | $0 | $0 |
| Income before taxes | −$94.5M | −$84.9M | −$67.4M | −$59.7M | −$59.3M | −$45.2M | −$41.3M | −$29.4M | −$30.8M | −$29.3M | −$14.0M | −$12.6M |
| Income taxes | — | $50,000 | −$186,000 | — | $93,000 | — | $90,000 | — | — | −$1 | $83,000 | $1.8M |
| Net income | −$94.5M | −$84.8M | −$67.6M | −$59.7M | −$59.4M | −$45.2M | −$41.4M | −$29.4M | −$30.8M | −$29.3M | −$14.1M | −$12.6M |
| EBITDA | −$93.8M | −$84.2M | −$57.9M | −$59.2M | −$58.8M | −$44.7M | −$40.8M | −$29.0M | −$30.5M | −$29.0M | −$13.9M | −$12.5M |
| EPS (diluted) | −$1.09 | −$0.99 | −$0.81 | −$0.85 | −$0.85 | −$0.65 | −$0.64 | −$0.54 | −$0.58 | −$0.55 | −$0.33 | −$0.33 |
| Gross margin | 100.0% | 24.1% | 39.5% | 25.4% | 96.9% | 96.7% | 93.0% | 93.0% | 85.2% | 93.5% | 92.9% | 92.1% |
| Operating margin | −19,207.1% | −12,532.5% | −11,346.0% | −6,420.8% | −1,166.8% | −199.7% | −390.4% | −311.2% | −364.5% | −285.2% | −116.6% | −94.7% |
| Net margin | −18,633.1% | −12,188.5% | −10,904.7% | −6,183.4% | −1,114.3% | −184.8% | −357.3% | −279.0% | −325.3% | −250.6% | −100.5% | −83.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in EYPT's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
EYPT financial results
In fiscal year 2025 (ended December 31, 2025), EyePoint Pharmaceuticals reported revenue of $31.4 million, down 27.5% from the year before. It had a net loss of $232.0 million, a net profit margin of −739.4%. Diluted earnings per share came to −$3.16. Over five years revenue grew at an average rate of −1.8% a year.
See the EYPT stock overview for the latest quote and news, or the EYPT chart for price history and technical indicators.
EYPT income statement FAQ
What is EyePoint Pharmaceuticals's annual revenue?
EyePoint Pharmaceuticals reported total revenue of $31.4 million for fiscal year 2025, which ended on December 31, 2025. That was down 27.5% from $43.3 million the previous year.
Is EyePoint Pharmaceuticals profitable?
No. EyePoint Pharmaceuticals reported a net loss of $232.0 million in fiscal 2025, a net profit margin of −739.4%; its operating margin was −776.0%.
What is EyePoint Pharmaceuticals's gross margin?
EyePoint Pharmaceuticals's gross margin was 93.4% in fiscal 2025: for every $100 of revenue, EyePoint Pharmaceuticals kept $93 after the direct cost of its products and services.
How much does EyePoint Pharmaceuticals spend on research and development?
EyePoint Pharmaceuticals spent $221.0 million on research and development in fiscal 2025, 704.6% of revenue.
How fast is EyePoint Pharmaceuticals growing?
Revenue grew −1.8% a year on average over the last five fiscal years, from $34.4 million to $31.4 million.
What are EyePoint Pharmaceuticals's earnings per share?
EyePoint Pharmaceuticals earned $-3.16 per diluted share in fiscal 2025, compared with $-2.31 a year earlier.
When will EyePoint Pharmaceuticals report its next earnings?
EyePoint Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens.
When does EyePoint Pharmaceuticals's fiscal year end?
EyePoint Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.